IP Library Granted Patent US 10,000,772
Granted Patent B2
US 10,000,772 · App. 14/685,502 · Granted Jun 19, 2018

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

Inventors: Jennifer A. Doudna (Berkeley, CA); Martin Jinek (Berkeley, CA); Emmanuelle Charpentier (Braunschweig, DE); Krzysztof Chylinski (Vienna, AT)
Assignees: The Regents of the University of California; University of Vienna; Emmanuelle Charpentier
C12N15/907C12N9/22C12N15/102C12N15/111C12N15/113C12N15/63C12N15/70C12N15/746C12N15/90C12N15/902C12N2310/11C12N2310/13C12N2310/20C12N2310/3519C12N2310/531C12N2800/80C12Y301/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,000,772
App. No.
14/685,502
Granted
Jun 19, 2018
Kind
B2
Abstract

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Claims (19)

1. A method of modifying a target DNA molecule, the method comprising:

contacting a target DNA molecule having a target sequence with a complex comprising:

(a) a Cas9 protein; and

(b) a DNA-targeting RNA comprising:

(i) a targeter-RNA that hybridizes with the target sequence, and

(ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA (dsRNA) duplex of a protein-binding segment,

wherein the activator-RNA hybridizes with the targeter-RNA to form a total of 10 to 15 base pairs,

wherein said contacting takes place outside of a bacterial cell and outside of an archaeal cell,

thereby resulting in modification of the target DNA molecule.

2. The method of claim 1 , wherein said modification of the target DNA molecule is cleavage of the target DNA molecule.

3. The method of claim 1 , wherein the target sequence is 15 nucleotides (nt) to 18 nt long.

4. The method of claim 1 , wherein the target sequence is 18 nucleotides (nt) to 25 nt long.

5. The method of claim 1 , wherein the target DNA molecule is chromosomal DNA.

6. The method of claim 1 , wherein the activator-RNA comprises the 26 nucleotide tracrRNA sequence set forth in SEQ ID NO: 441.

7. The method of claim 1 , wherein the targeter-RNA and/or the activator-RNA comprises one or more of: a non-natural internucleoside linkage, a nucleic acid mimetic, a modified sugar moiety, and a modified nucleobase.

8. The method of claim 1 , wherein the targeter-RNA and/or the activator-RNA comprises one or more of: (i) a non-natural internucleoside linkage selected from a phosphorothioate, an inverted polarity linkage, and an abasic nucleoside linkage; (ii) a locked nucleic acid (LNA); and (iii) a modified sugar moiety selected from 2′-O-methoxyethyl, 2′-O-methyl, and 2′-fluoro.

9. The method of claim 1 , wherein the targeter-RNA and/or the activator-RNA comprises one or more of: a peptide nucleic acid (PNA), a morpholino nucleic acid, a cyclohexenyl nucleic acid (CeNA), and/or a locked nucleic acid (LNA).

10. The method of claim 1 , wherein the targeter-RNA and/or the activator-RNA comprises one or more modified sugar moieties selected from: 2′-O-(2-methoxyethyl), 2′-dimethylaminooxyethoxy, 2′-dimethylaminoethoxyethoxy, 2′-O-methyl, and 2′-fluoro.

11. The method of claim 1 , wherein the targeter-RNA and/or the activator-RNA is conjugated to a moiety selected from: a polyamine; a polyamide; a polyethylene glycol; a polyether; a cholesterol moiety; a cholic acid; a thioether; a thiocholesterol; an aliphatic chain; a phospholipid; an adamantane acetic acid; a palmityl moiety; an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety; a biotin; a phenazine; a folate; a phenanthridine; an anthraquinone; an acridine; a fluorescein; a rhodamine; a fluor; and a coumarin.

Assignments (4)
CONFIRMATORY LICENSE Recorded Mar 17, 2017
From: UNIVERSITY OF CALIFORNIA BERKELEY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042038/0919 →
CORRECTIVE ASSIGNMENT TO CORRECT THE LAST NAME OF THE 4TH INVENTOR PREVIOUSLY RECORDED AT REEL: 038554 FRAME: 0746. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 23, 2016
From: DOUDNA, JENNIFER A.; JINEK, MARTIN; QI, LEI S.; DOUDNA CATE, JAMES HARRISON; LIM, WENDELL A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 038788/0626 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2016
From: CHYLINSKI, KRZYSZTOF
To: UNIVERSITY OF VIENNA
Reel/Frame 038554/0702 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2016
From: DOUDNA, JENNIFER A.; JINEK, MARTIN; QI, LEI S.; CATE, JAMES HARRISON DOUDNA; LIM, WENDELL A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 038554/0746 →
Continuity (6)
Continuation 13842859 · Mar 15, 2013
Provisional Application 61765576 · Feb 15, 2013
Provisional Application 61757640 · Jan 28, 2013
Provisional Application 61716256 · Oct 19, 2012
Provisional Application 61652086 · May 25, 2012
Related Publication 20160130608A1 · May 12, 2016
Cited By (4)
US 12,241,096 US 12,252,706 US 12,311,034 US 12,509,703